Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

miR17~92 restrains pro-apoptotic BIM to ensure survival of haematopoietic stem and progenitor cells.

Brinkmann K, Ng AP, de Graaf CA, Di Rago L, Hyland CD, Morelli E, Rautela J, Huntington ND, Strasser A, Alexander WS, Herold MJ.

Cell Death Differ. 2019 Oct 7. doi: 10.1038/s41418-019-0430-6. [Epub ahead of print]

PMID:
31591473
2.

Modeling breast cancer using CRISPR/Cas9-mediated engineering of human breast organoids.

Dekkers JF, Whittle JR, Vaillant F, Chen HR, Dawson C, Liu K, Geurts M, Herold MJ, Clevers H, Lindeman GJ, Visvader JE.

J Natl Cancer Inst. 2019 Oct 7. pii: djz196. doi: 10.1093/jnci/djz196. [Epub ahead of print]

PMID:
31589320
3.

Single-Cell Transcriptomics Identifies the Adaptation of Scart1+ Vγ6+ T Cells to Skin Residency as Activated Effector Cells.

Tan L, Sandrock I, Odak I, Aizenbud Y, Wilharm A, Barros-Martins J, Tabib Y, Borchers A, Amado T, Gangoda L, Herold MJ, Schmidt-Supprian M, Kisielow J, Silva-Santos B, Koenecke C, Hovav AH, Krebs C, Prinz I, Ravens S.

Cell Rep. 2019 Jun 18;27(12):3657-3671.e4. doi: 10.1016/j.celrep.2019.05.064.

4.

ROCK1 but not LIMK1 or PAK2 is a key regulator of apoptotic membrane blebbing and cell disassembly.

Tixeira R, Phan TK, Caruso S, Shi B, Atkin-Smith GK, Nedeva C, Chow JDY, Puthalakath H, Hulett MD, Herold MJ, Poon IKH.

Cell Death Differ. 2019 May 1. doi: 10.1038/s41418-019-0342-5. [Epub ahead of print]

PMID:
31043701
5.

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.

Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, Ramnac C, Hobbs C, Zhu H, Gunasingh G, Segal D, Behren A, Cebon J, Dobrovic A, Mariadason JM, Strasser A, Rohrbeck L, Haass NK, Herold MJ, Fairlie WD.

Cell Death Dis. 2019 Apr 24;10(5):342. doi: 10.1038/s41419-019-1568-3.

6.

Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects.

Delbridge ARD, Kueh AJ, Ke F, Zamudio NM, El-Saafin F, Jansz N, Wang GY, Iminitoff M, Beck T, Haupt S, Hu Y, May RE, Whitehead L, Tai L, Chiang W, Herold MJ, Haupt Y, Smyth GK, Thomas T, Blewitt ME, Strasser A, Voss AK.

Cell Rep. 2019 Apr 9;27(2):442-454.e5. doi: 10.1016/j.celrep.2019.03.048.

7.

Transcription Factor PU.1 Promotes Conventional Dendritic Cell Identity and Function via Induction of Transcriptional Regulator DC-SCRIPT.

Chopin M, Lun AT, Zhan Y, Schreuder J, Coughlan H, D'Amico A, Mielke LA, Almeida FF, Kueh AJ, Dickins RA, Belz GT, Naik SH, Lew AM, Bouillet P, Herold MJ, Smyth GK, Corcoran LM, Nutt SL.

Immunity. 2019 Jan 15;50(1):77-90.e5. doi: 10.1016/j.immuni.2018.11.010. Epub 2019 Jan 2.

PMID:
30611612
8.

Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence.

Fu NY, Pal B, Chen Y, Jackling FC, Milevskiy M, Vaillant F, Capaldo BD, Guo F, Liu KH, Rios AC, Lim N, Kueh AJ, Virshup DM, Herold MJ, Tucker HO, Smyth GK, Lindeman GJ, Visvader JE.

Dev Cell. 2018 Dec 3;47(5):629-644.e8. doi: 10.1016/j.devcel.2018.10.001. Epub 2018 Oct 25.

PMID:
30523786
9.

VDAC2 enables BAX to mediate apoptosis and limit tumor development.

Chin HS, Li MX, Tan IKL, Ninnis RL, Reljic B, Scicluna K, Dagley LF, Sandow JJ, Kelly GL, Samson AL, Chappaz S, Khaw SL, Chang C, Morokoff A, Brinkmann K, Webb A, Hockings C, Hall CM, Kueh AJ, Ryan MT, Kluck RM, Bouillet P, Herold MJ, Gray DHD, Huang DCS, van Delft MF, Dewson G.

Nat Commun. 2018 Nov 26;9(1):4976. doi: 10.1038/s41467-018-07309-4.

10.

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.

Almeida FF, Tognarelli S, Marçais A, Kueh AJ, Friede ME, Liao Y, Willis SN, Luong K, Faure F, Mercier FE, Galluso J, Firth M, Narni-Mancinelli E, Rais B, Scadden DT, Spallotta F, Weil S, Giannattasio A, Kalensee F, Zöller T, Huntington ND, Schleicher U, Chiocchetti AG, Ugolini S, Herold MJ, Shi W, Koch J, Steinle A, Vivier E, Walzer T, Belz GT, Ullrich E.

Oncoimmunology. 2018 Aug 15;7(10):e1475875. doi: 10.1080/2162402X.2018.1475875. eCollection 2018.

11.

GM-CSF Quantity Has a Selective Effect on Granulocytic vs. Monocytic Myeloid Development and Function.

Sun L, Rautela J, Delconte RB, Souza-Fonseca-Guimaraes F, Carrington EM, Schenk RL, Herold MJ, Huntington ND, Lew AM, Xu Y, Zhan Y.

Front Immunol. 2018 Aug 28;9:1922. doi: 10.3389/fimmu.2018.01922. eCollection 2018.

12.

Characterisation of mice lacking the inflammatory caspases-1/11/12 reveals no contribution of caspase-12 to cell death and sepsis.

Salvamoser R, Brinkmann K, O'Reilly LA, Whitehead L, Strasser A, Herold MJ.

Cell Death Differ. 2019 Jun;26(6):1124-1137. doi: 10.1038/s41418-018-0188-2. Epub 2018 Aug 28.

PMID:
30154447
13.

Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use.

Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, Kelly GL, Herold MJ.

Blood. 2018 Oct 11;132(15):1573-1583. doi: 10.1182/blood-2018-06-859405. Epub 2018 Aug 23.

PMID:
30139826
14.

TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1.

Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, Mojsa B, Damiano MA, Mora S, Lassot I, Ravichandran R, Cochet C, Aouacheria A, Potts PR, Herold MJ, Desagher S, Kucharczak J.

Cell Death Differ. 2019 May;26(5):902-917. doi: 10.1038/s41418-018-0169-5. Epub 2018 Jul 24.

PMID:
30042493
15.

Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins.

Trezise S, Karnowski A, Fedele PL, Mithraprabhu S, Liao Y, D'Costa K, Kueh AJ, Hardy MP, Owczarek CM, Herold MJ, Spencer A, Shi W, Willis SN, Nutt SL, Corcoran LM.

Int J Mol Sci. 2018 Jul 24;19(8). pii: E2161. doi: 10.3390/ijms19082161.

16.

MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway.

Wilson KR, Liu H, Healey G, Vuong V, Ishido S, Herold MJ, Villadangos JA, Mintern JD.

PLoS One. 2018 Jul 12;13(7):e0200540. doi: 10.1371/journal.pone.0200540. eCollection 2018.

17.

DNA repair processes are critical mediators of p53-dependent tumor suppression.

Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, Yang H, Tai L, Vandenberg CJ, Kueh AJ, Mizutani S, Brennan MS, Schenk RL, Lindqvist LM, Papenfuss AT, O'Connor L, Strasser A, Herold MJ.

Nat Med. 2018 Jul;24(7):947-953. doi: 10.1038/s41591-018-0043-5. Epub 2018 Jun 11.

PMID:
29892060
18.

Loss of NF-κB1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT-1-Dependent Manner.

O'Reilly LA, Putoczki TL, Mielke LA, Low JT, Lin A, Preaudet A, Herold MJ, Yaprianto K, Tai L, Kueh A, Pacini G, Ferrero RL, Gugasyan R, Hu Y, Christie M, Wilcox S, Grumont R, Griffin MDW, O'Connor L, Smyth GK, Ernst M, Waring P, Gerondakis S, Strasser A.

Immunity. 2018 Mar 20;48(3):570-583.e8. doi: 10.1016/j.immuni.2018.03.003.

19.

CRISPR/Cas9: A tool for immunological research.

Hochheiser K, Kueh AJ, Gebhardt T, Herold MJ.

Eur J Immunol. 2018 Apr;48(4):576-583. doi: 10.1002/eji.201747131. Epub 2018 Feb 26. Review.

20.

Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.

Mensink M, Anstee NS, Robati M, Schenk RL, Herold MJ, Cory S, Vandenberg CJ.

Cell Death Differ. 2018 Mar;25(4):797-808. doi: 10.1038/s41418-017-0045-8. Epub 2018 Jan 16.

21.

How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?

Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A.

Cell Death Differ. 2018 Jan;25(1):104-113. doi: 10.1038/cdd.2017.169. Epub 2017 Nov 17. Review.

22.

DNA-binding of the Tet-transactivator curtails antigen-induced lymphocyte activation in mice.

Ottina E, Peperzak V, Schoeler K, Carrington E, Sgonc R, Pellegrini M, Preston S, Herold MJ, Strasser A, Villunger A.

Nat Commun. 2017 Oct 18;8(1):1028. doi: 10.1038/s41467-017-01022-4.

23.

Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells.

Fitzsimmons L, Boyce AJ, Wei W, Chang C, Croom-Carter D, Tierney RJ, Herold MJ, Bell AI, Strasser A, Kelly GL, Rowe M.

Cell Death Differ. 2018 Feb;25(2):241-254. doi: 10.1038/cdd.2017.150. Epub 2017 Sep 29.

24.

The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice.

Brinkmann K, Grabow S, Hyland CD, Teh CE, Alexander WS, Herold MJ, Strasser A.

Cell Death Differ. 2017 Dec;24(12):2032-2043. doi: 10.1038/cdd.2017.125. Epub 2017 Aug 11.

25.

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ.

Sci Transl Med. 2017 Aug 2;9(401). pii: eaam7049. doi: 10.1126/scitranslmed.aam7049.

PMID:
28768804
26.

An update on using CRISPR/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles.

Kueh AJ, Pal M, Tai L, Liao Y, Smyth GK, Shi W, Herold MJ.

Cell Death Differ. 2017 Oct;24(10):1821-1822. doi: 10.1038/cdd.2017.122. Epub 2017 Jul 28. No abstract available.

27.

DR5 and caspase-8 are dispensable in ER stress-induced apoptosis.

Glab JA, Doerflinger M, Nedeva C, Jose I, Mbogo GW, Paton JC, Paton AW, Kueh AJ, Herold MJ, Huang DC, Segal D, Brumatti G, Puthalakath H.

Cell Death Differ. 2017 May;24(5):944-950. doi: 10.1038/cdd.2017.53. Epub 2017 Apr 14.

28.

Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo.

Carrington EM, Zhan Y, Brady JL, Zhang JG, Sutherland RM, Anstee NS, Schenk RL, Vikstrom IB, Delconte RB, Segal D, Huntington ND, Bouillet P, Tarlinton DM, Huang DC, Strasser A, Cory S, Herold MJ, Lew AM.

Cell Death Differ. 2017 May;24(5):878-888. doi: 10.1038/cdd.2017.30. Epub 2017 Mar 31.

29.

Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells.

Chen HC, Joalland N, Bridgeman JS, Alchami FS, Jarry U, Khan MWA, Piggott L, Shanneik Y, Li J, Herold MJ, Herrmann T, Price DA, Gallimore AM, Clarkson RW, Scotet E, Moser B, Eberl M.

Immunol Cell Biol. 2017 Aug;95(7):620-629. doi: 10.1038/icb.2017.21. Epub 2017 Mar 30.

30.

A non-canonical function of Ezh2 preserves immune homeostasis.

Vasanthakumar A, Xu D, Lun AT, Kueh AJ, van Gisbergen KP, Iannarella N, Li X, Yu L, Wang D, Williams BR, Lee SC, Majewski IJ, Godfrey DI, Smyth GK, Alexander WS, Herold MJ, Kallies A, Nutt SL, Allan RS.

EMBO Rep. 2017 Apr;18(4):619-631. doi: 10.15252/embr.201643237. Epub 2017 Feb 21.

31.

Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.

Tanzer MC, Khan N, Rickard JA, Etemadi N, Lalaoui N, Spall SK, Hildebrand JM, Segal D, Miasari M, Chau D, Wong WL, McKinlay M, Chunduru SK, Benetatos CA, Condon SM, Vince JE, Herold MJ, Silke J.

Cell Death Differ. 2017 Mar;24(3):481-491. doi: 10.1038/cdd.2016.147. Epub 2017 Jan 20.

32.

MDM4 is a rational target for treating breast cancers with mutant p53.

Miranda PJ, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, Jochemsen A, Haupt S, Haupt Y.

J Pathol. 2017 Apr;241(5):661-670. doi: 10.1002/path.4877. Epub 2017 Mar 1.

PMID:
28097652
33.

The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infection.

Tuzlak S, Schenk RL, Vasanthakumar A, Preston SP, Haschka MD, Zotos D, Kallies A, Strasser A, Villunger A, Herold MJ.

Cell Death Differ. 2017 Mar;24(3):523-533. doi: 10.1038/cdd.2016.155. Epub 2017 Jan 13.

34.

Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment.

Schenk RL, Tuzlak S, Carrington EM, Zhan Y, Heinzel S, Teh CE, Gray DH, Tai L, Lew AM, Villunger A, Strasser A, Herold MJ.

Cell Death Differ. 2017 Mar;24(3):534-545. doi: 10.1038/cdd.2016.156. Epub 2017 Jan 13.

35.

Male sterility in Mcl-1-flox mice is not due to enhanced Mcl1 protein stability.

Ah-Cann C, Tailler M, Kueh AJ, Herold MJ, Opferman JT, Asselin-Labat ML, Bouillet P.

Cell Death Dis. 2016 Dec 1;7(12):e2490. doi: 10.1038/cddis.2016.391. No abstract available.

36.

CRISPR/Cas9-The ultimate weapon to battle infectious diseases?

Doerflinger M, Forsyth W, Ebert G, Pellegrini M, Herold MJ.

Cell Microbiol. 2017 Feb;19(2). doi: 10.1111/cmi.12693. Epub 2016 Dec 6. Review.

PMID:
27860197
37.

Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer.

Berger S, Procko E, Margineantu D, Lee EF, Shen BW, Zelter A, Silva DA, Chawla K, Herold MJ, Garnier JM, Johnson R, MacCoss MJ, Lessene G, Davis TN, Stayton PS, Stoddard BL, Fairlie WD, Hockenbery DM, Baker D.

Elife. 2016 Nov 2;5. pii: e20352. doi: 10.7554/eLife.20352.

38.

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O.

Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.

PMID:
27760111
39.

Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.

Rohrbeck L, Gong JN, Lee EF, Kueh AJ, Behren A, Tai L, Lessene G, Huang DC, Fairlie WD, Strasser A, Herold MJ.

Cell Death Differ. 2016 Dec;23(12):2054-2062. doi: 10.1038/cdd.2016.96. Epub 2016 Sep 30.

40.

Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Paul PJ, Raghu D, Chan AL, Gulati T, Lambeth L, Takano E, Herold MJ, Hagekyriakou J, Vessella RL, Fedele C, Shackleton M, Williams ED, Fox S, Williams S, Haupt S, Gamell C, Haupt Y.

Oncogene. 2016 Dec 1;35(48):6235-6245. doi: 10.1038/onc.2016.159. Epub 2016 Sep 19.

PMID:
27641331
41.

RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice.

Delbridge AR, Pang SH, Vandenberg CJ, Grabow S, Aubrey BJ, Tai L, Herold MJ, Strasser A.

J Exp Med. 2016 Sep 19;213(10):2039-48. doi: 10.1084/jem.20150477. Epub 2016 Sep 12.

42.

The new editor-targeted genome engineering in the absence of homology-directed repair.

Kueh AJ, Herold MJ.

Cell Death Discov. 2016 Jun 13;2:16042. doi: 10.1038/cddiscovery.2016.42. eCollection 2016. No abstract available.

43.

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, Khaw SL, Lessene G, Spencer A, Herold MJ, Roberts AW, Huang DCS.

Blood. 2016 Oct 6;128(14):1834-1844. doi: 10.1182/blood-2016-03-704908. Epub 2016 Jul 27.

PMID:
27465916
44.

Using CRISPR/Cas9 Technology for Manipulating Cell Death Regulators.

Kueh AJ, Herold MJ.

Methods Mol Biol. 2016;1419:253-64. doi: 10.1007/978-1-4939-3581-9_18.

PMID:
27108444
45.

BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.

Xu Z, Sharp PP, Yao Y, Segal D, Ang CH, Khaw SL, Aubrey BJ, Gong J, Kelly GL, Herold MJ, Strasser A, Roberts AW, Alexander WS, Burns CJ, Huang DC, Glaser SP.

Leukemia. 2016 Jul;30(7):1531-41. doi: 10.1038/leu.2016.52. Epub 2016 Mar 8.

PMID:
27055867
46.

Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.

Valente LJ, Aubrey BJ, Herold MJ, Kelly GL, Happo L, Scott CL, Newbold A, Johnstone RW, Huang DC, Vassilev LT, Strasser A.

Cell Rep. 2016 Mar 1;14(8):1858-66. doi: 10.1016/j.celrep.2016.01.059. Epub 2016 Feb 18.

47.

Targeting Mdmx to treat breast cancers with wild-type p53.

Haupt S, Buckley D, Pang JM, Panimaya J, Paul PJ, Gamell C, Takano EA, Lee YY, Hiddingh S, Rogers TM, Teunisse AF, Herold MJ, Marine JC, Fox SB, Jochemsen A, Haupt Y.

Cell Death Dis. 2015 Jul 16;6:e1821. doi: 10.1038/cddis.2015.173.

48.

NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5.

Baker PJ, Boucher D, Bierschenk D, Tebartz C, Whitney PG, D'Silva DB, Tanzer MC, Monteleone M, Robertson AA, Cooper MA, Alvarez-Diaz S, Herold MJ, Bedoui S, Schroder K, Masters SL.

Eur J Immunol. 2015 Oct;45(10):2918-26. doi: 10.1002/eji.201545655. Epub 2015 Aug 24.

49.

Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells.

Carrington EM, Zhang JG, Sutherland RM, Vikstrom IB, Brady JL, Soo P, Vremec D, Allison C, Lee EF, Fairlie WD, Bouillet P, Grabow S, Ottina E, Herold MJ, Pellegrini M, Huang DC, Tarlinton DM, Strasser A, Lew AM, Zhan Y.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):4044-9. doi: 10.1073/pnas.1417620112. Epub 2015 Mar 16.

50.

An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo.

Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O'Connor L, Milla L, Wilcox S, Tai L, Strasser A, Herold MJ.

Cell Rep. 2015 Mar 3;10(8):1422-32. doi: 10.1016/j.celrep.2015.02.002. Epub 2015 Feb 26.

Supplemental Content

Loading ...
Support Center